Healthcare Industry News: bendamustine
News Release - July 31, 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business UnitFRAZER, Pa., July 31 (Healthcare Sales & Marketing Network) -- Cephalon, Inc. (Nasdaq: CEPH ) announced today that Craig C. Phillips has been appointed as Vice President and General Manager of the Oncology Business Unit. In this role, Phillips will have responsibility for managing all aspects of the U.S. oncology business including Sales, Marketing and Medical Affairs.
"Since joining Cephalon two years ago, Craig has clearly demonstrated an ability to exceed expectations and bring value to our organization through his leadership," said Robert Roche, Executive Vice President, Worldwide Pharmaceutical Operations. "I am confident that Craig's leadership and vision will support the dynamic growth of the Cephalon Oncology business and allow us to continue to bring medicines that matter to the healthcare professionals and patients battling cancer."
Phillips joined Cephalon in 2007 as Senior Group Director of Sales, National Accounts and Sales Training, for the Oncology Business Unit. Under his leadership, his sales team was instrumental in 2008 for the successful U.S. introduction of two indications for TREANDA(R) (bendamustine HCl) for Injection, the most recent addition to the Cephalon Oncology portfolio. Prior to joining Cephalon, Phillips spent 15 years at Johnson & Johnson and has more than 22 years of pharmaceutical industry experience.
Phillips earned his Bachelor's degree from Miami University in Oxford, Ohio.
About Cephalon Oncology
Cephalon, a leading biopharmaceutical company, is building a diversified portfolio of oncology products that represents a comprehensive approach to extend and enhance the lives of patients with cancer. Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio includes a number of promising investigational and marketed compounds. The therapeutic portfolio in the United States includes two marketed products: TREANDA, which is approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen and TRISENOX(R) (arsenic trioxide) injection, approved for the treatment of patients with relapsed or refractory acute promyelocytic leukemia.
In Europe, Cephalon markets three additional oncology products in 19 countries.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.
Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key affiliates are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.
The company's proprietary products in the United States include: NUVIGIL(R) (armodafinil) Tablets [C-IV], TREANDA, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, GABITRIL(R) (tiagabine hydrochloride), PROVIGIL(R) (modafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, continuation of growth of the Cephalon Oncology business, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.